2 Items on Genzyme Ireland FDA-483
FDA has released the form FDA-483 issued following a 1/9-1/17 inspection at the Genzyme Ireland drug manufacturing facility in Waterford, Ireland. The two inspection observations were:
- failure to establish procedures, processes, and testing designed to prevent microbial contamination of the drug product purporting to be sterile; and
- failure to adequately maintain redacted systems in support of drug manufacture.